LncRNA DLG2-AS1 as a Novel Biomarker in Lung Adenocarcinoma
Metadatos
Mostrar el registro completo del ítemAutor
Arenas Molina, Alberto Manuel; Cuadros Celorrio, Marta Eugenia; Andrades Delgado, Álvaro; García García, Daniel Jesús; F. Coira, Isabel; Rodríguez, María Isabel; Baliñas Gavira, Carlos; Peinado, Paola; Álvarez Pérez, Juan Carlos; P. Medina, PedroEditorial
Mdpi
Materia
Adenocarcinoma of lung Biomarkers Tumor RNA Long noncoding
Fecha
2020-07-28Referencia bibliográfica
Arenas, A. M., Cuadros, M., Andrades, A., García, D. J., Coira, I. F., Rodríguez, M. I., ... & Medina, P. P. (2020). LncRNA DLG2-AS1 as a Novel Biomarker in Lung Adenocarcinoma. Cancers, 12(8), 2080. [doi:10.3390/cancers12082080]
Patrocinador
Spanish Ministry of Economy and Business SAF2015-67919-R; Junta de Andalucía CS2016-3 Pl-0245-2017; Asociación Española Contra el Cáncer (AECC) Foundation LabAECC2018; International Association for the Study of Lung Cancer (IASLC)'s Young Investigator Award 2017; Spanish Ministry of Education, Culture and Sports FPU fellowship FPU17/01258 FPU17/00067; "Fundacion Benefica Anticancer Santa Candida y San Francisco Javier" predoctoral fellowship; Spanish Ministry of Economy and Business FPI fellowship BES-2013-064596; La Caixa Foundation LCF/BQ/DE15/10360019; Marie Sklodowska Curie Actions postdoctoral fellowship (H2020-MSCA-IF-2018) 837897Resumen
Long non-coding RNAs (lncRNAs) are a heterogeneous class of non-coding RNAs whose
biological roles are still poorly understood. LncRNAs serve as gene expression regulators, frequently
interacting with epigenetic factors to shape the outcomes of crucial biological processes, and playing
roles in di erent pathologies including cancer. Over the last years, growing scientific evidence
supports the key role of some lncRNAs in tumor development and proposes them as valuable
biomarkers for the clinic. In this study, we aimed to characterize lncRNAs whose expression is
altered in tumor samples from patients with lung adenocarcinoma (LUAD) compared to adjacent
normal tissue samples. On an RT-qPCR survey of 90 cancer-related lncRNAs, we found one lncRNA,
DLG2-AS1, which was consistently downregulated in 70 LUAD patients. To gain insight into its
biological function, DLG2-AS1 was cloned and successfully re-expressed in LUAD cancer cell lines.
We determined that DLG2-AS1 is not a cis-regulatory element of its overlapping gene DLG2, as their
transcription levels were not correlated, nor did DLG2-AS1 restoration modify the expression of
DLG2 protein. Furthermore, after generating a receiver operating curve (ROC) and calculating the
area under curve (AUC), we found that DLG2-AS1 expression showed high sensitivity and specificity
(AUC = 0.726) for the classification of LUAD and normal samples, determining its value as a potential
lung cancer biomarker.